Population
158,325 commercially insured medical patients in the US aged ≥40 years with a hospitalisation claim for…
Design
Cohort
Follow-up
median time to VTE 74 days
Authors
Loading...
Patients with cancer or prior VTE face elevated post-discharge VTE risk; hypothesis-generating for targeted prophylaxis trials.
Commercially insured medical patients, particularly those with cancer or prior VTE, are at high risk for post-discharge venous thromboembolism despite low rates of prescribed prophylaxis.
Hussein et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: